Mylan Reports Adjusted Diluted EPS of $0.32 for the Quarter Ended June 30, 2009

Adjusted Diluted EPS for the Six Months Ended June 30, 2009 is $0.65

PITTSBURGH, July 30 /PRNewswire-FirstCall/ -- Mylan Inc. (Nasdaq: MYL) today
announced its financial results for the three and six months ended June 30,
2009.

Financial Highlights

-- Adjusted diluted EPS, which excludes the impact of certain purchase
accounting items as well as other non-cash and/or non-recurring items
as
detailed below, was $0.32 and $0.65 for the three and six months ended
June 30, 2009, compared to $0.20 and $0.29 for the same prior year
periods;
-- Total revenues of $1.27 billion for the three months ended June 30,
2009, an increase of $63.9 million over the same prior year period;
-- Total revenues of $2.48 billion for the six months ended June 30,
2009,
an increase of $199.3 million over the same prior year period;

-- On a GAAP basis, the company reported diluted EPS of $0.19 and $0.42
for
the three and six months ended June 30, 2009, compared to a loss per
share of $0.05 and $1.52 in the same prior year periods. The six
months
ended June 30, 2008 included a non-cash goodwill impairment charge of
$385.0 million related to the Specialty Segment.

Mylan's Chairman and CEO Robert J. Coury commented: "This was yet another
successful quarter on many fronts for Mylan as, across the board, we delivered
another quarter of financial performance that exceeded our expectations. Our
powerful and integrated global platform enabled each of our businesses to
generate year-over-year quarterly revenue growth on a constant currency basis
and to deliver additional operational efficiencies as well. In addition, we
took an important initial step in one of our targeted areas of future growth
by entering into a collaborative agreement with Biocon in the area of generic
biologics."

Coury continued: "On the strength of the momentum provided by our first half
results, coupled with what we now forecast to be a much stronger second half,
we are very pleased to once again be increasing our full year 2009 adjusted
diluted EPS guidance. At the mid-point of our new guidance range of $1.13 to
$1.20, we're now projecting year-over-year growth in full year adjusted
diluted EPS of approximately 45%."

Financial Summary

Total revenues for the quarter ended June 30, 2009, increased by $63.9
million, or 5.3%, to $1.27 billion, from $1.20 billion in the same prior year
period. Increased revenues were realized by all three of Mylan's reportable
segments, Generics, Specialty and Matrix, as further discussed below.
Excluding the unfavorable effect of foreign currency translation, primarily
reflecting a stronger U.S. dollar, year-over-year revenue growth on a constant
currency basis would have been approximately 13%.

Generics revenues, which are derived from sales in North America, Europe, the
Middle East and Africa (collectively, EMEA) and Asia Pacific were $1.03
billion in the current quarter, compared to $983.1 million in the same prior
year period.

Total revenues from North America were $533.3 million for the three months
ended June 30, 2009, compared to $452.0 million for the same prior year
period, representing an increase of 18.0%.

Revenues from products launched in the U.S. subsequent to June 30, 2008, and
increased volume were primarily responsible for the increase in revenues,
partially offset by unfavorable pricing as a result of additional generic
competition on certain products. In the current quarter, new products
contributed revenues of $112.2 million, primarily consisting of Divalproex
Sodium Extended-release (Divalproex), which Mylan launched in the first
quarter of 2009.

Total revenues from EMEA were $367.8 million in the current quarter, compared
to $389.8 million in the same prior year period, a decrease of 5.6%. On a
constant currency basis, EMEA revenues increased by nearly 10% over the prior
year period. Higher revenues in France, EMEA's largest market, and the U.K.
served to offset lower revenue in Germany. In France, revenues increased as a
result of higher volumes and new product launches, while prior period revenues
in the U.K. were negatively impacted by excess supply that existed in the
market at that time. Also contributing to EMEA revenues were sales from the
Central and Eastern European businesses, which Mylan acquired from Merck KGaA
in June 2008.

Sales in Asia Pacific are derived from Mylan's operations in Australia, Japan
and New Zealand. Asia Pacific revenues were $127.9 million in the current
quarter, compared to $141.4 million in the same prior year period, a decrease
of 9.5%. On a constant currency basis, sales were slightly higher in the
current quarter. This increase was driven by higher revenues in Japan as a
result of continued pro-generic measures implemented by the Japanese
government as well as new product launches. Additionally, in Australia, the
effects of a government-mandated price reduction, which went into effect in
July 2008, were more than offset by higher volumes and new products.

Specialty, consisting of Mylan's Dey business, which focuses on the
development, manufacture and marketing of specialty pharmaceuticals in the
respiratory and severe allergy markets, reported third-party sales of $122.8
million, an increase of 16.0% from third-party sales of $105.9 million for the
three months ended June 30, 2008. Perforomist(R), Dey's Formoterol Fumarate
Inhalation Solution (Perforomist), and EpiPen(R), Dey's Epinephrine
auto-injector (EpiPen), were the primary drivers of the increase in revenues.

Matrix reported third-party revenues of $116.9 million for the three months
ended June 30, 2009, compared to $104.6 million for the same prior year
period, representing an increase of 11.7%. On a constant currency basis,
year-over-year revenue growth would have been approximately 29%. Matrix's
revenues increased primarily as a result of higher sales of first-line
anti-retroviral (ARV) products from the Company's finished dosage form (FDF)
business.

Gross profit for the three months ended June 30, 2009, was $527.8 million and
gross margins were 41.7%. Excluding certain purchase accounting items, gross
margins would have been 47.2% in the current quarter compared to 43.7% in the
same prior year period. Margin improvement was realized by all three of
Mylan's segments, driven primarily by products launched subsequent to June 30,
2008, and continued integration synergies.

Gross margins in the current quarter were negatively impacted by certain
purchase accounting items of approximately $70.1 million, which consisted
primarily of amortization related to purchased intangible assets. In the same
prior year period, gross margins were negatively impacted by similar items,
which amounted to approximately $112.1 million.

Earnings from operations were $174.7 million for the three months ended June
30, 2009, compared to $74.0 million in the same prior year period. Excluding
purchase accounting items from both periods, earnings from operations would
have been $244.8 million in the current quarter, compared to $186.1 million in
the prior year.

The increase in operating income in the current quarter is due to increased
sales and gross profit, as well as lower R&D expense, partially offset by
higher SG&A expense.

SG&A expense increased in the current quarter primarily due to higher payroll
and payroll related costs and increased legal and consulting costs, including
those associated with the purchase, during the quarter, of additional shares
in Matrix. Both SG&A and R&D expense in the current quarter were favorably
impacted by the effect of the stronger U.S. dollar and by synergies realized
as a result of the company's ongoing restructuring initiatives.

Interest expense for the current quarter totaled $78.2 million, compared to
$92.4 million for the three months ended June 30, 2008. This decrease is
primarily the result of the reduction of outstanding debt balances through
repayments made in December 2008 and March 2009, as well as lower overall
interest rates. Other income, net, for the current quarter was $25.3 million,
which included a $13.9 million favorable adjustment to the Company's
restructuring reserve as a result of a reduction in the estimated remaining
spending on accrued projects and a gain of approximately $10.4 million on the
termination of two 50% owned joint ventures with Aspen Pharmacare Holdings
Limited of South Africa.

Total revenues for the six months ended June 30, 2009, increased by $199.3
million, or 8.8%, to $2.48 billion, from $2.28 billion in the same prior year
period. As with the quarter, increased revenues were realized by all three of
Mylan's reportable segments. On a constant currency basis, year-over-year
revenue growth would have been approximately 17%.

Also included in total revenues for the six months ended June 30, 2009 are
other revenues of $52.7 million, which increased by $24.8 million from the
same prior year period. This increase is primarily the result of the
acceleration of the recognition of revenue related to certain product
development arrangements that had been previously deferred.

Generics revenues were $2.06 billion in the six months ended June 30, 2009,
compared to $1.89 billion in the same prior year period.

Total revenues from North America were $1.12 billion for the six months ended
June 30, 2009, compared to $840.8 million for the same prior year period,
representing an increase of 33.1%. This increase was the result of new
product revenue of $250.1 million, mainly Divalproex, and higher volumes,
partially offset by unfavorable pricing.

Mylan's Fentanyl Transdermal System (Fentanyl), Mylan's AB-rated generic
alternative to Duragesic(R), continued to contribute significantly to both
revenue and gross profit despite the entrance into the market of additional
generic competition. Sales of Fentanyl have remained relatively strong
primarily due to Mylan's ability to continue to be a stable and reliable
source of supply to the market.

Total revenues from EMEA were $700.6 million in the current quarter, compared
to $778.7 million in the same prior year period, a decrease of 10.0%. On a
constant currency basis, EMEA revenues would have increased by nearly 5%.
Higher revenues in France, driven mainly by new product launches, and a full
six months of revenue contribution from the Central and Eastern European
businesses served to offset lower revenues brought about by continued pricing
pressures in certain European markets such as Germany and Portugal.

Asia Pacific revenues were $236.9 million in the current quarter, compared to
$270.2 million in the same prior year period, a decrease of 12.3%. On a
constant currency basis, sales in the current year would have been essentially
flat.

Specialty reported third-party sales of $202.2 million, compared to $183.0
million for the six months ended June 30, 2008. EpiPen was the primary driver
of the increase in revenues. Higher sales of Perforomist were offset by lower
sales of DuoNeb(R), which continues to experience the unfavorable impact of
generic competition, which first entered the market in 2007.

Matrix reported third-party revenues of $219.5 million for the six months
ended June 30, 2009, compared to $192.3 million for the same prior year
period, representing an increase of 14.2%. On a constant currency basis,
year-over-year revenue growth would have been approximately 35%, driven by
increased sales of ARV FDF products.

Gross profit for the six months ended June 30, 2009, was $1.05 billion and
gross margins were 42.5%. Excluding certain purchase accounting items totaling
$139.1 million for the six months ended June 30, 2009, and $230.2 million in
the same prior year period, gross margins would have been 48.1% compared to
43.7%. The increase in gross margins was driven primarily by products
launched subsequent to June 30, 2008, and continued integration synergies.

Earnings from operations were $402.1 million for the six months ended June 30,
2009, compared to a loss from operations of $297.5 million in the same prior
year period, which included a non-cash goodwill impairment charge of $385.0
million. Excluding purchase accounting items from both periods, as well as the
non-cash impairment charge from the prior year, earnings from operations would
have been $541.2 million in the current year, compared to $317.7 million in
the prior year.

The increase in operating income in the current year is due to increased sales
and gross profit, as well as lower overall operating expenses. Additionally,
earnings from operations in the current year include approximately $28.5
million of incremental revenue resulting from the acceleration of the
recognition of revenue related to certain product development arrangements as
discussed above.

Operating expenses decreased overall as a result of the favorable effect of
the stronger U.S. dollar and by synergies realized as a result of the
company's ongoing restructuring initiatives. In addition, the prior year
included higher costs as a result of a greater amount of activity associated
with the integration of the former Merck Generics business. Partially
offsetting these favorable items were increased professional and consulting
fees as well as higher payroll and payroll related costs.

Interest expense for the current year totaled $163.2 million, compared to
$188.9 million for the six months ended June 30, 2008. This decrease is
primarily the result of the reduction of outstanding debt balances through
repayments made in December 2008 and March 2009, as well as lower overall
interest rates.

EBITDA, which is defined as net income (loss) (excluding the non-controlling
interest and income from equity method investees) plus income taxes, interest
expense, depreciation and amortization, was $299.1 million for the quarter
ended June 30, 2009 and $625.8 million for the six months then ended. After
adjusting for certain non-recurring or non-cash items as further discussed
below, adjusted EBITDA was $316.6 million and $641.5 million for the three and
six months, respectively.

Non-GAAP Financial Measures

Mylan is disclosing non-GAAP financial measures when providing financial
results. Primarily due to acquisitions, Mylan believes that an evaluation of
its ongoing operations (and comparisons of its current operations with
historical and future operations) would be difficult if the disclosure of its
financial results were limited to financial measures prepared only in
accordance with accounting principles generally accepted in the U.S. (GAAP).
In addition to disclosing its financial results determined in accordance with
GAAP, Mylan is disclosing non-GAAP results that exclude items such as
amortization expense and other costs directly associated with the acquisitions
as well as certain other non-recurring and non-cash expenses and revenue in
order to supplement investors' and other readers' understanding and assessment
of the company's financial performance because the company's management uses
these measures internally for forecasting, budgeting and measuring its
operating performance. In addition, the company believes that including EBITDA
and supplemental adjustments applied in presenting adjusted EBITDA is
appropriate to provide additional information to investors to demonstrate the
company's ability to comply with financial debt covenants (which are
calculated using a measure similar to adjusted EBITDA) and assess the
company's ability to incur additional indebtedness. Whenever Mylan uses such a
non-GAAP measure, it will provide a reconciliation of non-GAAP financial
measures to the most closely applicable GAAP financial measure. Investors and
other readers are encouraged to review the related GAAP financial measures and
the reconciliation of non-GAAP measures to their most closely applicable GAAP
measure set forth below and should consider non-GAAP measures only as a
supplement to, not as a substitute for or as a superior measure to, measures
of financial performance prepared in accordance with GAAP.

Below is a reconciliation of Mylan's results as reported under GAAP to its
adjusted results for the three and six months ended June 30, 2009:

Three Months Ended Six Months Ended
June 30, 2009 June 30, 2009
------------------------- -------------------------
As As
GAAP Adjustments Adjusted GAAP Adjustments Adjusted
------------------------- -------------------------

Total revenues 1,267.0 (2.3) a 1,264.7 2,476.9 (30.8) a 2,446.1
Cost of sales 739.2 (72.8) b 666.4 1,423.4 (149.2) b 1,274.2
----- ----- ----- ------- ------ -------

Gross profit 527.8 70.5 598.3 1,053.5 118.4 1,171.9

Operating expenses:
Research and
development 74.0 (18.6) c 55.4 132.9 (22.2) c 110.7
Selling, general and
administrative 279.7 (20.4) a 259.3 521.3 (33.5) a 487.8
Litigation
settlements, net (0.6) 0.6 - (2.8) 2.8 -
---- --- - ---- --- -
Total operating
expenses 353.1 (38.4) 314.7 651.4 (52.9) 598.5
----- ----- ----- ----- ----- -----

Earnings from
operations 174.7 108.9 283.6 402.1 171.3 573.4
Interest expense 78.2 (10.7) d 67.5 163.2 (20.9) d 142.3
Other income, net 25.3 (23.8) e 1.5 29.5 (23.8) e 5.7
---- ----- --- ---- ----- ---

Earnings before
income taxes and
noncontrolling
interest 121.8 95.8 217.6 268.4 168.4 436.8
Income tax provision 26.2 44.2 f 70.4 63.6 72.4 f 136.0
---- ---- ---- ---- ---- -----

Net earnings before
noncontrolling
interest 95.6 51.6 147.2 204.8 96.0 300.8
Net (earnings) loss
attributable to the
noncontrolling
interest (2.8) 3.0 g 0.2 (5.8) 3.0 g (2.8)
---- --- --- ---- --- ----
Net earnings
attributable to
Mylan Inc. before
preferred dividends 92.8 54.6 147.4 199.0 99.0 298.0
Preferred dividends 34.8 (34.8) h - 69.5 (69.5) h -
---- ----- - ---- ----- -
Net earnings
attributable to
Mylan Inc. common
shareholders $58.0 $89.4 $147.4 $129.5 $168.5 $298.0
===== ===== ====== ====== ====== ======

Diluted earnings per
common share
attributable to
Mylan Inc: $0.19 $0.32 $0.42 $0.65
===== ===== ===== =====

Diluted weighted
average common
shares outstanding: 306.3 152.8 h 459.1 305.8 152.8 h 458.6
===== ===== ===== ===== ===== =====

(a) This adjustment relates to Integration and other non-recurring items,
which includes charges principally related to the acquisition and
integration of the former Merck Generics business (e.g., non-recurring
professional and consulting fees and other non-recurring expenses) as
well as certain restructuring and non-recurring revenue items.
(b) This amount consists primarily of amortization expense related to
purchased intangible assets in the amount of $70.1 million and
$139.1 million for the three and six months, respectively. The
remainder in each period relates to integration and other
non-recurring items. See footnote (a).
(c) This amount includes a one-time charge related to an upfront payment
made with respect to the Company's execution of a co-development
agreement during the quarter ended June 30, 2009, and integration and
other non-recurring items. See footnote (a).
(d) Represents non-cash interest on the Company's convertible notes.
(e) Included in this amount is a $13.9 million favorable adjustment to the
Company's restructuring reserve as a result of a reduction in the
estimated remaining spending on accrued projects and a gain of
approximately $10.4 million on the termination of two 50% owned joint
ventures with Aspen Pharmacare Holdings Limited of South Africa. The
remainder in each period relates to integration and other
non-recurring items. See footnote (a).
(f) The tax effect is calculated assuming an annual adjusted effective tax
rate for the resulting adjusted earnings, and results in a year to
date (and annual) adjusted effective tax rate on adjusted earnings of
31% including the impact of tax synergies.
(g) The gain of $10.4 million described in footnote (e) was recorded by
the Company's majority-owned subsidiary. As this gain was excluded
from adjusted earnings, an adjustment was recorded to also exclude
from net earnings the amounts attributable to the noncontrolling
interest with respect to this gain.
(h) Adjusted diluted EPS for the three and six months ended June 30, 2009,
were calculated under the "if-converted method" which assumes
conversion of the company's preferred stock into a maximum of
152.8 million shares of common stock and excludes the preferred
dividend from the calculation. The "if-converted" method was more
dilutive to adjusted diluted EPS for the three and six month periods
by approximately $0.05 per share and $0.09 per share, respectively.

Below is a reconciliation of GAAP net earnings attributable to Mylan Inc. to
adjusted EBITDA for the three and six months ended June 30, 2009:

Three months Six months
ended ended
(in millions) June 30, 2009 June 30, 2009
------------- -------------

GAAP net earnings attributable to Mylan Inc. $92.9 $198.9
Add/(Deduct):
Net earnings attributable to the
noncontrolling interest 2.8 5.8
Income from equity method investees (0.5) (1.3)
Income taxes 26.2 63.6
Interest expense 78.2 163.2
Depreciation & amortization 99.5 195.6
---- -----
EBITDA 299.1 625.8
Add/(Deduct) Adjustments:
Non-cash stock-based compensation expense 6.2 14.7
Litigation settlements, net (0.6) (2.8)
Integration and other non-recurring items 11.9 3.8
Adjusted EBITDA $316.6 $641.5
====== ======

Conference Call

Mylan will host a conference call and live webcast today, Thursday, July 30,
2009, at 8:30 a.m. ET, in conjunction with the release of its financial
results. The dial-in number to access the July 30 call is 877.857.6176 or
719.325.4764 for international callers. A replay, available for approximately
seven days, will be available at 888.203.1112 or 719.457.0820 for
international callers with access pass code 1742471. To access a live webcast
of the call, please log on to Mylan's Web site (www.mylan.com) at least 15
minutes before the event is to begin to register and download or install any
necessary software. A replay of the webcast will be available on www.mylan.com
for approximately seven days.

About Mylan

Mylan Inc., which provides products to customers in more than 140 countries
and territories, ranks among the leading diversified generic and specialty
pharmaceutical companies in the world. The company maintains one of the
industry's broadest -- and highest quality -- product portfolios, supported by
a robust product pipeline; owns a controlling interest in the world's third
largest active pharmaceutical ingredient manufacturer; and operates a
specialty business focused on respiratory and allergy therapies. For more
information, please visit www.mylan.com.

Forward Looking Statements

This press release includes statements that constitute "forward-looking
statements", including with regard to the company's future operations and its
earnings expectations. These statements are made pursuant to the safe harbor
provisions of the Private Securities Litigation Reform Act of 1995. Because
such statements inherently involve risks and uncertainties, actual future
results may differ materially from those expressed or implied by such
forward-looking statements. Factors that could cause or contribute to such
differences include, but are not limited to: challenges, risks and costs
inherent in business integrations and in achieving anticipated synergies; the
effect of any changes in customer and supplier relationships and customer
purchasing patterns; general market perception of the acquisition of the
former Merck Generics business; the ability to attract and retain key
personnel; changes in third-party relationships; the impacts of competition;
changes in economic and financial conditions of the company's business;
uncertainties and matters beyond the control of management; inherent
uncertainties involved in the estimates and judgments used in the preparation
of financial statements, and the providing of estimates of financial measures,
in accordance with GAAP and related standards. These cautionary statements
should be considered in connection with any subsequent written or oral
forward-looking statements that may be made by the company or by persons
acting on its behalf and in conjunction with its periodic SEC filings. In
addition, please refer to the cautionary statements and risk factors set forth
in the company's Report on Form 10-Q, for the quarter ended Mar. 31, 2009, and
in its other filings with the SEC. Further, uncertainties or other
circumstances, or matters outside of the company's control between the date of
this release and the date that its Form 10-Q for the quarter ended June 30,
2009 is filed with the SEC could potentially result in adjustments to reported
results. The company undertakes no obligation to update statements herein for
revisions or changes after the date of this release.

Mylan Inc. and Subsidiaries
Condensed Consolidated Statements of Operations
(Unaudited; in thousands, except per share amounts)

Three Months Ended Six Months Ended
June 30, June 30, June 30, June 30,
2009 2008 2009 2008
---- ---- ---- ----
As As
Adjusted* Adjusted*

Revenues:
Net revenues $1,255,798 $1,187,258 $2,424,160 $2,249,670
Other revenues 11,179 15,864 52,733 27,912
------ ------ ------ ------

Total revenues 1,266,977 1,203,122 2,476,893 2,277,582
Cost of sales 739,210 788,912 1,423,393 1,513,150
------- ------- --------- ---------

Gross profit 527,767 414,210 1,053,500 764,432
------- ------- --------- -------

Operating expenses:
Research and development 74,016 80,753 132,853 164,599
Impairment loss on
goodwill - - - 385,000
Selling, general and
administrative 279,672 259,357 521,344 512,269
Litigation settlements, net (634) 100 (2,751) 100
---- --- ------ ---
Total operating expenses 353,054 340,210 651,446 1,061,968
------- ------- ------- ---------

Earnings (loss) from
operations 174,713 74,000 402,054 (297,536)
Interest expense 78,172 92,386 163,175 188,865
Other income, net 25,308 7,855 29,498 14,816
------ ----- ------ ------

Earnings (loss) before income
taxes and noncontrolling
interest 121,849 (10,531) 268,377 (471,585)
Income tax provision
(benefit) 26,178 (28,905) 63,632 (76,026)
------ ------- ------ -------

Net earnings (loss) 95,671 18,374 204,745 (395,559)
Net (earnings) loss
attributable to the
noncontrolling
interest (2,801) 72 (5,816) 2,114
------ -- ------ -----
Net earnings (loss)
attributable to Mylan Inc.
before preferred dividends 92,870 18,446 198,929 (393,445)
Preferred dividends 34,759 34,759 69,518 69,477
------ ------ ------ ------
Net earnings (loss)
attributable to Mylan Inc.
common shareholders $58,111 $(16,313) $129,411 $(462,922)
======= ======== ======== =========

Earnings (loss) per common
share attributable to
Mylan Inc.:
Basic $0.19 $(0.05) $0.42 $(1.52)
===== ====== ===== ======
Diluted $0.19 $(0.05) $0.42 $(1.52)
===== ====== ===== ======

Weighted average common
shares outstanding:
Basic 304,991 304,284 304,784 304,233
======= ======= ======= =======
Diluted 306,256 304,284 305,759 304,233
======= ======= ======= =======

* Adjusted to reflect the adoption of FSP APB No. 14-1

Mylan Inc. and Subsidiaries
Condensed Consolidated Balance Sheets
(Unaudited; in thousands)

June 30, 2009 December 31, 2008
------------- -----------------
As Adjusted*
Assets:
Current assets:
Cash and cash equivalents $429,477 $557,147
Restricted cash 56,050 40,309
Available-for-sale securities 30,117 42,260
Accounts receivable, net 1,140,605 1,164,613
Inventories 1,077,088 1,065,990
Other current assets 289,238 304,354
------- -------
Total current assets 3,022,575 3,174,673
Intangible assets, net 2,429,344 2,453,161
Goodwill 3,179,083 3,161,580
Other non-current assets 1,611,682 1,620,445
--------- ---------
Total assets $10,242,684 $10,409,859
=========== ===========

Liabilities:
Current liabilities $1,421,417 $1,544,650
Long-term debt 4,978,289 5,078,937
Other non-current liabilities 930,690 999,431
------- -------
Total liabilities 7,330,396 7,623,018
Noncontrolling interest 16,235 29,108
Mylan Inc. shareholders' equity 2,896,053 2,757,733
--------- ---------
Total liabilities and shareholders' equity $10,242,684 $10,409,859
=========== ===========

* Adjusted to reflect the adoption of FSP APB No. 14-1

SOURCE Mylan Inc.

Media: Michael Laffin, +1-724-514-1968, or Investors: Dan Crookshank,
+1-724-514-1813, both for Mylan Inc.